Endocrine adverse events related to immune-oncology agents

Immune-oncology agents (IOA) represent a turning point in the treatment of several solid tumors (ST). Although their toxicity compares favorably with other treatments, IOA associate immune-related adverse events (IR-AE), among which endocrine-related AE stand out. We retrospectively evaluated the oc...

Descripción completa

Detalles Bibliográficos
Autores: España, Sofia|||0000-0002-7825-0734, Pérez-Montes de Oca, Alejandra|||0000-0001-8807-1935, Marqués Pamies, Montserrat|||0000-0001-6391-5070, Cucurull, Marc|||0000-0003-2588-567X, Domènech, Marta|||0000-0003-4827-9170, Velarde, Jose María, Salinas, Isabel, Morán, Teresa, Etxaniz, Olatz|||0000-0002-8856-5596
Tipo de recurso: artículo
Fecha de publicación:2020
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:303206
Acceso en línea:https://ddd.uab.cat/record/303206
https://dx.doi.org/urn:doi:10.21037/tlcr.2019.12.17
Access Level:acceso abierto
Palabra clave:Anti-PD-1/PD-L1
Anti-ctla-4
Endocrine-immune related adverse events
Solid tumors (ST)
id ES_aad0daa78a71c085eae0dfe2f74acf8c
oai_identifier_str oai:ddd.uab.cat:303206
network_acronym_str ES
network_name_str España
repository_id_str
spelling Endocrine adverse events related to immune-oncology agentsretrospective experience of a single institutionEspaña, Sofia|||0000-0002-7825-0734Pérez-Montes de Oca, Alejandra|||0000-0001-8807-1935Marqués Pamies, Montserrat|||0000-0001-6391-5070Cucurull, Marc|||0000-0003-2588-567XDomènech, Marta|||0000-0003-4827-9170Velarde, Jose MaríaSalinas, IsabelMorán, TeresaEtxaniz, Olatz|||0000-0002-8856-5596Anti-PD-1/PD-L1Anti-ctla-4Endocrine-immune related adverse eventsSolid tumors (ST)Immune-oncology agents (IOA) represent a turning point in the treatment of several solid tumors (ST). Although their toxicity compares favorably with other treatments, IOA associate immune-related adverse events (IR-AE), among which endocrine-related AE stand out. We retrospectively evaluated the occurrence of endocrine (E) IR-AE in a cohort of patients with several ST treated with IOA. In addition, we assessed the correlation between likelihood of survival and the occurrence of IR-AE. We collected data on clinical and molecular characteristics, efficacy and AE of 260 patients with ST treated with IOA from 2013 to 2017. We excluded patients with prior conditions or treatments potentially affecting thyroid test results. Lung cancer was the most prevalent diagnosis (70.2%). EIR-AE appeared in 18.1% of patients (total of 38 EIR-AE) and consisted of hypothyroidism, hyperthyroidism, pituitary disorders and type 1 diabetes mellitus in 60.5%, 21.1%, 15.8% and 2.6% of patients, respectively. EIR-AE were associated mainly to nivolumab, nivolumab plus ipilimumab (41.2% and 26.5%) and appeared after a median of 4.2 cycles of treatment. Specific therapy was required in 65.8% patients. There were significant differences in both progression-free survival (PFS) and overall survival (OS) for patients who experienced EIR-AE compared to those who did not [PFS: 56.7 (NC-NC) vs. 27.7 (14.3-41.3) months, P=0.008; OS: NC (NC-NC) vs. 31.4 (20.7-42.1) months, P=0.001]. The incidence of EIR-AE in our study is similar to other series. Patients who develop EIR-AE might have a better prognosis compared to those who do not experience them. 22020-01-0120202020-01-01Articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/303206https://dx.doi.org/urn:doi:10.21037/tlcr.2019.12.17reponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengAgencia Estatal de Investigación https://doi.org/10.13039/501100011033 RTI2018-093901-B-I00Agència de Gestió d'Ajuts Universitaris i de Recerca https://doi.org/10.13039/501100003030 2017/SGR-94open accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.https://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:3032062026-06-06T12:50:31Z
dc.title.none.fl_str_mv Endocrine adverse events related to immune-oncology agents
retrospective experience of a single institution
title Endocrine adverse events related to immune-oncology agents
spellingShingle Endocrine adverse events related to immune-oncology agents
España, Sofia|||0000-0002-7825-0734
Anti-PD-1/PD-L1
Anti-ctla-4
Endocrine-immune related adverse events
Solid tumors (ST)
title_short Endocrine adverse events related to immune-oncology agents
title_full Endocrine adverse events related to immune-oncology agents
title_fullStr Endocrine adverse events related to immune-oncology agents
title_full_unstemmed Endocrine adverse events related to immune-oncology agents
title_sort Endocrine adverse events related to immune-oncology agents
dc.creator.none.fl_str_mv España, Sofia|||0000-0002-7825-0734
Pérez-Montes de Oca, Alejandra|||0000-0001-8807-1935
Marqués Pamies, Montserrat|||0000-0001-6391-5070
Cucurull, Marc|||0000-0003-2588-567X
Domènech, Marta|||0000-0003-4827-9170
Velarde, Jose María
Salinas, Isabel
Morán, Teresa
Etxaniz, Olatz|||0000-0002-8856-5596
author España, Sofia|||0000-0002-7825-0734
author_facet España, Sofia|||0000-0002-7825-0734
Pérez-Montes de Oca, Alejandra|||0000-0001-8807-1935
Marqués Pamies, Montserrat|||0000-0001-6391-5070
Cucurull, Marc|||0000-0003-2588-567X
Domènech, Marta|||0000-0003-4827-9170
Velarde, Jose María
Salinas, Isabel
Morán, Teresa
Etxaniz, Olatz|||0000-0002-8856-5596
author_role author
author2 Pérez-Montes de Oca, Alejandra|||0000-0001-8807-1935
Marqués Pamies, Montserrat|||0000-0001-6391-5070
Cucurull, Marc|||0000-0003-2588-567X
Domènech, Marta|||0000-0003-4827-9170
Velarde, Jose María
Salinas, Isabel
Morán, Teresa
Etxaniz, Olatz|||0000-0002-8856-5596
author2_role author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Anti-PD-1/PD-L1
Anti-ctla-4
Endocrine-immune related adverse events
Solid tumors (ST)
topic Anti-PD-1/PD-L1
Anti-ctla-4
Endocrine-immune related adverse events
Solid tumors (ST)
description Immune-oncology agents (IOA) represent a turning point in the treatment of several solid tumors (ST). Although their toxicity compares favorably with other treatments, IOA associate immune-related adverse events (IR-AE), among which endocrine-related AE stand out. We retrospectively evaluated the occurrence of endocrine (E) IR-AE in a cohort of patients with several ST treated with IOA. In addition, we assessed the correlation between likelihood of survival and the occurrence of IR-AE. We collected data on clinical and molecular characteristics, efficacy and AE of 260 patients with ST treated with IOA from 2013 to 2017. We excluded patients with prior conditions or treatments potentially affecting thyroid test results. Lung cancer was the most prevalent diagnosis (70.2%). EIR-AE appeared in 18.1% of patients (total of 38 EIR-AE) and consisted of hypothyroidism, hyperthyroidism, pituitary disorders and type 1 diabetes mellitus in 60.5%, 21.1%, 15.8% and 2.6% of patients, respectively. EIR-AE were associated mainly to nivolumab, nivolumab plus ipilimumab (41.2% and 26.5%) and appeared after a median of 4.2 cycles of treatment. Specific therapy was required in 65.8% patients. There were significant differences in both progression-free survival (PFS) and overall survival (OS) for patients who experienced EIR-AE compared to those who did not [PFS: 56.7 (NC-NC) vs. 27.7 (14.3-41.3) months, P=0.008; OS: NC (NC-NC) vs. 31.4 (20.7-42.1) months, P=0.001]. The incidence of EIR-AE in our study is similar to other series. Patients who develop EIR-AE might have a better prognosis compared to those who do not experience them.
publishDate 2020
dc.date.none.fl_str_mv 2
2020-01-01
2020
2020-01-01
dc.type.none.fl_str_mv Article
http://purl.org/coar/resource_type/c_6501
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://ddd.uab.cat/record/303206
https://dx.doi.org/urn:doi:10.21037/tlcr.2019.12.17
url https://ddd.uab.cat/record/303206
https://dx.doi.org/urn:doi:10.21037/tlcr.2019.12.17
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.relation.none.fl_str_mv Agencia Estatal de Investigación https://doi.org/10.13039/501100011033 RTI2018-093901-B-I00
Agència de Gestió d'Ajuts Universitaris i de Recerca https://doi.org/10.13039/501100003030 2017/SGR-94
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Dipòsit Digital de Documents de la UAB
instname:Universitat Autònoma de Barcelona
instname_str Universitat Autònoma de Barcelona
reponame_str Dipòsit Digital de Documents de la UAB
collection Dipòsit Digital de Documents de la UAB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869416214467444736
score 15,811543

Similares en LA Referencia